Journal
DEVELOPMENTAL CELL
Volume 49, Issue 3, Pages 425-+Publisher
CELL PRESS
DOI: 10.1016/j.devcel.2019.04.014
Keywords
-
Categories
Funding
- NIH [R01CA187090]
- Toulmin Pilot Award
- Sher Grant
- Cancer Center Support Grant [CA051008]
- V foundation
- DF/HCC Kidney Cancer Spore [P50-CA101942-10]
- Children's Tumor Foundation
- Advocure Foundation
- National Science Foundation Graduate Research Fellowship (NSF-GRF) [2018265935]
- [R01CA193698]
Ask authors/readers for more resources
Merlin/NF2 is a bona fide tumor suppressor whose mutations underlie inherited tumor syndrome neuro-fibromatosis type 2 (NF2), as well as various sporadic cancers including kidney cancer. Multiple Merlin/NF2 effector pathways including the Hippo-YAP/TAZ pathway have been identified. However, the molecular mechanisms underpinning the growth and survival of NF2-mutant tumors remain poorly understood. Using an inducible orthotopic kidney tumor model, we demonstrate that YAP/TAZ silencing is sufficient to induce regression of pre-established NF2-deficient tumors. Mechanistically, YAP/TAZ depletion diminishes glycolysis-dependent growth and increases mitochondria! respiration and reactive oxygen species (ROS) buildup, resulting in oxidativestress-induced cell death when challenged by nutrient stress. Furthermore, we identify lysosome-mediated cAMP-PKA/EPAC-dependent activation of RAF-MEK-ERK signaling as a resistance mechanism to YAP/TAZ inhibition. Finally, unbiased analysis of TCGA primary kidney tumor transcrip-tomes confirms a positive correlation of a YAP/TAZ signature with glycolysis and inverse correlations with oxidative phosphorylation and lysosomal gene expression, supporting the clinical relevance of our findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available